Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | DHODH | Q02127 | 5/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041155 | 0.90 | LMNA (0.65) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10864298 | 0.89 | LMNA (0.52) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27810073 | 0.83 | MAPT (0.62) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4204786 | 0.79 | LMNA (0.64) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28693800 | 0.76 | KDM4E (0.72) | LMNAHPGDKDM4EALDH1A1MAPT | |
| SCHEMBL27830629 | 0.76 | RXFP1 (0.59) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1898539 | 0.76 | DHODH (0.80) | LMNASMN1; SMN2KDM4EDHODHKMT2A | |
| SCHEMBL29788460 | 0.76 | DHODH (0.80) | LMNASMN1; SMN2KDM4EDHODHKMT2A | |
| SCHEMBL4274235 | 0.76 | ALDH1A1 (0.53) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10866597 | 0.76 | TP53 (0.57) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| WO-2002000623-A2 | ARYL FUSED SUBSTITUTED 4-OXY-PYRIDINES | NEUROGEN CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002000623-A2 | ARYL FUSED SUBSTITUTED 4-OXY-PYRIDINES | NEUROGEN CORPORATION (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | LMNA 577/4885HPGD 1375/4885SMN1; SMN2 1244/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | LMNA 579/4885HPGD 1608/4885SMN1; SMN2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.